IPP Bureau
Bayer confirms 2025 targets after solid start to the year
By IPP Bureau - May 14, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
.jpg "Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr")
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
By IPP Bureau - May 14, 2025
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
By IPP Bureau - May 14, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Briefs: Zydus and CuraTeQ Biologics
By IPP Bureau - May 14, 2025
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
By IPP Bureau - May 14, 2025
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
By IPP Bureau - May 14, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa
By IPP Bureau - May 13, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Borealis advancing sustainability medical devices with the Bornewables
By IPP Bureau - May 13, 2025
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025
Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
Wanbury's Tanuku facility granted GMP certificate by ANVISA
By IPP Bureau - May 13, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity
By IPP Bureau - May 13, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Morepen Board proposed dividend after 23 years
By IPP Bureau - May 13, 2025
Scores highest PAT of Rs. 118 crore in FY25
